KT-300 / Kayak Therapeutics, Shattuck - LARVOL DELTA

TRIM7 inhibition blocks RTK/RAS pathway driven tumor proliferation independent of mutation and in the setting of KRASi resistance (AACR 2026) - "Therapeutics that more broadly target this pathway, like the multi-KRAS isoform inhibitor daraxonrasib, offer promise in less common mutations (e.g., KRAS G12X/Q61X). TRIM7 inhibition via KT-300 may offer broad, mutation-agnostic activity in RTK-KRAS driven cancers. This represents a novel "pan-RTK-KRAS pathway inhibition" strategy that could extend efficacy to complex mutational backgrounds not addressed by current KRAS inhibitors, including in patients who have developed resistance to existing RTK-KRAS targeted therapies."

Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR • KRAS • NRAS • STAT3 • TRIM7